Amikacin Dosing for Urinary Tract Infections
For uncomplicated UTIs in adults with normal renal function, amikacin 250 mg twice daily is the FDA-approved regimen, though 15 mg/kg once daily (maximum 1.5 g/day) represents the standard dosing for more severe infections. 1
Standard Dosing for UTIs
Uncomplicated UTI (Normal Renal Function)
- 250 mg twice daily (FDA-labeled indication) 1
- Alternative: 15 mg/kg once daily for more severe presentations 2
- Duration: 7-10 days 1
Complicated UTI or Pyelonephritis
- 15 mg/kg once daily (maximum 1.5 g/day) 2, 1
- Can divide into 7.5 mg/kg every 12 hours or 5 mg/kg every 8 hours 1
- Once-daily dosing is preferred as it optimizes peak-dependent killing while potentially reducing nephrotoxicity 3
Renal Impairment Adjustments
Critical principle: Maintain the full milligram dose (12-15 mg/kg) but extend the dosing interval—do not reduce individual doses, as this compromises efficacy. 4
Dosing Interval Calculation
- Simple method: Multiply serum creatinine (mg/dL) × 9 = dosing interval in hours 1
- Example: Creatinine 2.0 mg/dL → dose every 18 hours
Stage-Specific Adjustments
- Stage 3A CKD (GFR 45-59): 7.5 mg/kg daily 5
- Stage 3B CKD (GFR 30-44): 4 mg/kg daily 5
- Stage 4 CKD (GFR 15-29): 4 mg/kg daily OR 6 mg/kg every 48 hours 5
- Hemodialysis: 5 mg/kg every 48 hours, given after dialysis 4, 5
- Peritoneal dialysis: 4 mg/kg every 48 hours 5
Important caveat: Every-other-day dosing in Stage 4 CKD may be less effective due to subtherapeutic trough levels—daily dosing with dose reduction is preferred when feasible 5.
Therapeutic Drug Monitoring
Target Levels
- Peak: 25-35 mcg/mL (daily dosing) or 65-80 mcg/mL (thrice-weekly dosing) 6
- Trough: <5 mcg/mL (ideally <1 mcg/mL to minimize toxicity) 6, 1
- Avoid: Peak >35 mcg/mL or trough >10 mcg/mL 1
Sampling Timing
- Peak: 60-90 minutes after infusion completion 6, 1
- Trough: Immediately before next dose 6, 1
- Frequency:
- First week: Peak level initially, then weekly
- Trough levels weekly × 4 weeks, then every 2 weeks if stable 6
Dose Adjustments Based on Levels
Safety Monitoring
Baseline Assessment
- Serum creatinine and calculate creatinine clearance 1
- Audiogram and vestibular testing 4
- Romberg test 4
During Therapy
- Renal function: Monitor creatinine weekly, more frequently if impaired 1
- Auditory/vestibular symptoms: Query monthly 4
- Electrolytes: Check potassium and magnesium if prolonged therapy 4
- Repeat audiogram: If any symptoms of ototoxicity develop 4
Risk Factors for Toxicity
- Nephrotoxicity (8.7% incidence): Pre-existing renal impairment, concurrent nephrotoxins (especially vancomycin), higher cumulative doses 4, 7
- Ototoxicity (1.5-24% hearing loss): Prolonged therapy, higher doses, concurrent loop diuretics, elderly patients 4
Critical pitfall: Patients with renal impairment require aggressive monitoring—failure to adjust dosing intervals leads to drug accumulation and toxicity 1, 7.
Administration Details
IV Infusion
- Dilute in 100-200 mL normal saline or 5% dextrose 1
- Adults: Infuse over 30-60 minutes 1
- Pediatrics/Infants: Infuse over 1-2 hours 1
- Stable for 24 hours at room temperature 1
Treatment Duration
- Uncomplicated UTI: 7-10 days 1
- Complicated UTI/Pyelonephritis: 7 days (β-lactams), though aminoglycoside duration less well-defined 8
- Beyond 10 days: Re-evaluate necessity; monitor drug levels and renal/auditory function closely 1
Special Populations
Obesity
- Use adjusted body weight: Ideal body weight + 0.4 × (actual weight - ideal body weight) 6
- Male IBW (kg) = 50 + 2.3 × (height in inches above 60)
- Female IBW (kg) = 45.5 + 2.3 × (height in inches above 60)
Pregnancy
- Contraindicated: Risk of fetal nephrotoxicity and congenital hearing loss 4
Elderly (>59 years)
Clinical Context
Amikacin retains excellent activity against ESBL-producing Enterobacterales and many multidrug-resistant organisms, making it valuable for complicated UTIs when other options are limited 9, 2. Recent data suggest nephrotoxicity risk may be lower than historically feared when properly dosed and monitored 10, 11. However, once-daily dosing with aggressive TDM is essential to balance efficacy against concentration-dependent toxicity 3, 12.
For carbapenem-resistant organisms, consider amikacin as part of combination therapy rather than monotherapy 9. Single-dose aminoglycoside therapy for simple cystitis due to resistant organisms is supported by guidelines, though specific amikacin data are limited 9.